RNA methylation‐related inhibitors: Biological basis and therapeutic potential for cancer therapy
Clinical and Translational Medicine · 2024-04 · 14 (4)
DOI: 10.1002/ctm2.1644 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Medicine, online erschienen am 04.04.2024. Verfasst von Huanxiang Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: RNA Methylation, Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 158 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Medical Science and Technology Provincial and Ministerial Co-Construction Project of Henan Province, Young and Middle-Aged Health Science and Technology Innovation Talents Project of Henan Province.
Abstract (Originalsprache)
RNA methylation is widespread in nature. Abnormal expression of proteins associated with RNA methylation is strongly associated with a number of human diseases including cancer. Increasing evidence suggests that targeting RNA methylation holds promise for cancer treatment. This review specifically describes several common RNA modifications, such as the relatively well‐studied N6‐methyladenosine, as well as 5‐methylcytosine and pseudouridine (Ψ). The regulatory factors involved in these modifications and their roles in RNA are also comprehensively discussed. We summarise the diverse regulatory functions of these modifications across different types of RNAs. Furthermore, we elucidate the structural characteristics of these modifications along with the development of specific inhibitors targeting them. Additionally, recent advancements in small molecule inhibitors targeting RNA modifications are presented to underscore their immense potential and clinical significance in enhancing therapeutic efficacy against cancer. Key Points In this paper, several important types of RNA modifications and their related regulatory factors are systematically summarised. Several regulatory factors related to RNA modification types were associated with cancer progression, and their relationships with cancer cell migration, invasion, drug resistance and immune environment were summarised. In this paper, the inhibitors targeting different regulators that have been proposed in recent studies are summarised in detail, which is of great significance for the development of RNA modification regulators and cancer treatment in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- School of Life Science, Zhengzhou University, Zhengzhou, China.
- Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China.
ORCID-Profile: Junhu Wan
Förderung
- National Natural Science Foundation of China
- Medical Science and Technology Provincial and Ministerial Co-Construction Project of Henan Province
- Young and Middle-Aged Health Science and Technology Innovation Talents Project of Henan Province
- Funding for Scientific Research and Innovation Team of The First Affiliated Hospital of Zhengzhou University
- Natural Science Foundation of Henan Province
- Zhengzhou University Education and Teaching Reform Research and Practice Project
Zitieren
APA
Chen, H., Liu, H., Zhang, C., Xiao, N., Li, Y., Zhao, X., Zhang, R., Gu, H., Kang, Q., & Wan, J. (2024). RNA methylation‐related inhibitors: Biological basis and therapeutic potential for cancer therapy. Clinical and Translational Medicine, 14(4). https://doi.org/10.1002/ctm2.1644
Vancouver
Chen H, Liu H, Zhang C, Xiao N, Li Y, Zhao X, et al. RNA methylation‐related inhibitors: Biological basis and therapeutic potential for cancer therapy. Clinical and Translational Medicine. 2024;14(4). doi:10.1002/ctm2.1644
BibTeX
@article{Chen2024,
author = {Chen, Huanxiang and Liu, Hongyang and Zhang, Chenxing and Xiao, Nan and Li, Yang and Zhao, Xiangzhuan and Zhang, Ruike and Gu, Huihui and Kang, Qiaozhen and Wan, Junhu},
title = {RNA methylation‐related inhibitors: Biological basis and therapeutic potential for cancer therapy},
journal = {Clinical and Translational Medicine},
year = {2024},
volume = {14},
number = {4},
doi = {10.1002/ctm2.1644}
}
EUVIMED